XI’AN, China, Oct. 12 /Xinhua-PRNewswire/ -- Worldwide Biotech & Pharmaceutical Group (''WWBP’’) successfully introduced its Chinese Golden Medal patented invention -- ''the Intact Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro by Cell Culture’’ to conventioneers when Ms Wenxia Guo, CEO and President of WWBP, attended the China Economic Summit held in Beijing.
As a core part of the 8th China Beijing International High-tech Exposition, which is held annually, the China Economic Summit mainly focuses on high-tech innovation and China’s sustainable economic growth. Because high-tech innovation was the main theme of the Summit, WWBP seized the opportunity by introducing a leading invention for medical technology named, HCV (Hepatitis C Virus), and more importantly, by this chance WWBP has won an initial success for its recognition and reputation. This Economic Summit has provided WWBP with a platform to introduce its achievement in HVC technology to all the attendants of the Summit across the world.
In fact, China is harboring a third of all chronic hepatitis B (HBV) sufferers and a fourth of chronic hepatitis C (HCV) sufferers, 120 million and 41 million people respectively. With this huge potential market, it is clear that the situation WWBP faces is prosperous and but also competitive.
''We are very thankful for being given such a great opportunity to attend the Economic Summit. The theme of this summit which is around innovation let us know that it’s the right time for WWBP to quicken the steps ahead to high-end technology development,’' said Wenxia Guo, CEO and President of WWBP, ''WWBP is a biotech company and the technological innovation is our core element. With this predominance, WWBP will quicken the stages of HCV development with all our strength.’'
About Worldwide Biotech & Pharmaceutical (Group) Co., Ltd.
Worldwide Biotech & Pharmaceutical Company (''WWBP’’) is a hi-tech biotech company with top-ranking pharmaceutical R&D abilities, Good Manufacturing Practices (GMP) licensed manufacturing facilities and a well-established marketing network in China and Southeast Asia. The product range of WWBP covers Hepatitis C Virus (HCV) products, diagnostic medicines and Over-The-Counter (OTC) drugs. WWBP currently possesses of 35,940 square meters of land and 5,359 square meters of GMP standard facilities. With strong pharmaceutical R&D abilities especially in the HCV field, WWBP has been known as the first biotech company in the world to hold the technology of culturing intact HCV in vitro by cell culture. Its principle project ''the Intact Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro by Cell Culture’’ was awarded with a Chinese patent by the China Patent Bureau and the prestigious China Patent Golden Medal by the World Intellectual Property Organization and China Patent Bureau. The medal is the only one issued for achievement in the biomedical sciences during the past 10 years. WWBP has achieved a GMP production scale level of 10,000 ml for concentrated HCV material and 10 grams HCV antigen per month, which is expected to bring WWBP considerable gross sale revenue each year and greatly strengthen the company’s R&D on anti-HCV drug screen and HCV human vaccine. WWBP has successfully reached two merger agreements with pharmaceutical companies in China, all of which have scalable production and well-established sales network and the acquiring is expected to be finished before the end of August 2005. The acquisitions will strengthen WWBP’s R&D abilities and production scale, as well as extend its marketing network throughout China and Southeast Asia. WWBP has been working closely with pharmaceutical research institutes, and has established connections with both central & local governments.
About the China Economic Summit
The China Economic Summit was held at the Great Hall of the People in Beijing on May 24, 2005 and, it is a main part of the 8th China Beijing International High-tech Exposition. This summit will focus on the following key items: ''2005 China Innovation Year’’, ''Financial Innovation’’, ''Enterprise Governing and China’s Economic Sustainable Growth.’' During the summit, a number of famous economists and entrepreneurs gave a brilliant debate on key areas. More information: http://www.chitec.cn .
About HCV (Hepatitis C Virus) Technology
HCV is a small, enveloped, single-stranded, blood-borne RNA virus in the family Flaviviridae. HCV is a major cause of liver disease in the United States and the world. WWBP has committed a large amount of cash and resources to the development of its cornerstone technology: a laboratory method for culturing (growing, propagating) intact Hepatitis C Virus. After three years of intensive research, the scientists at WWBP achieved a technological breakthrough for culturing HCV in vitro, making it the first to overcome the main hurdle to HCV research and product development. The breakthrough in establishing a cell culture system for HCV production and infection by WWBP scientists provides a potentially unlimited source for HCV and a comprehensive technology platform upon which the Company can be built. From this Rosetta stone, WWBP hopes to development new generation HCV diagnostics, new classes of HCV drugs, HCV vaccines and to be part of the development of next-generation anti-HCV targeted (gene) therapies.
Safe Harbor
Information in this news release may contain statements about future expectations, plans, prospects or performance of Worldwide Biotech & Pharmaceutical Co. that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. Worldwide Biotech & Pharmaceutical Co. cautions you that any forward-looking information provided by or on behalf of Worldwide Biotech & Pharmaceutical Co. is not a guarantee of future performance. None of the information on this website constitutes an offer to sell securities or investment advice of any kind, and visitors should not base their investment decisions on information contained in this website. Worldwide Biotech & Pharmaceutical Co.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Worldwide Biotech & Pharmaceutical Co.'s control. In addition to those discussed in Worldwide Biotech & Pharmaceutical Co.'s press releases, public filings, and statements by Worldwide Biotech & Pharmaceutical Co.'s management, including, but not limited to, Worldwide Biotech & Pharmaceutical Co.'s estimate of the sufficiency of its existing capital resources, Worldwide Biotech & Pharmaceutical Co.'s ability to raise additional capital to fund future operations, Worldwide Biotech & Pharmaceutical Co.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Worldwide Biotech & Pharmaceutical Co.'s capability to be awarded contracts. All such forward- looking statements are current only as of the date on which such statements were made. Worldwide Biotech & Pharmaceutical Co. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Worldwide Biotech & Pharmaceutical Company
CONTACT: Ivy Liu of Worldwide Biotech and Pharmaceutical Company,+86-29-8819-3338, or mobile, +86-135-1919-6011, or wwbp@worldwidebio.com
Web site: http://www.chitec.cn/